Administrative Core

MAVDA行政核心（MAC）将作为一个综合的、确定优先事项的联合体建立 包括项目总监（PD），业务总监（BD），内部MAVDA领导团队（MLT）， 和科学咨询委员会（SAB），由NIAID参与计划，以提高潜在的产品 以抗SAR-CoV-2和其他具有大流行潜力的病毒的抗病毒药物的形式取得成果。的 管理职能旨在提供行政支持，促进个人的成功 项目，促进有效整合和配置支持功能和资源，并激励 MAVDA成员之间的科学交流，从而确保整个计划实现其目标。 MAC将由共同PD，大卫S博士监督。Perlin和Charles M.赖斯将得到一位 经验丰富的业务拓展和适当的支持人员，以协调和管理所有行政职能。最好地 为了推进MAVDA的目标，MAC将协调项目负责人、制药/生物技术部门 合伙人、核心董事和SAB成员。这些会议旨在推动化合物通过 发现矩阵，实现及时和客观的“去/不去”决策。一个安全的网络平台将 用于促进项目和核心之间的互动。MAC将协助召开年度审查会议， SAB和NIAID的反向现场访问。它将向NIH提交年度进展报告， 它将协调研究出版物、会议介绍、报告和新闻稿。MAVDA设计 鼓励学术界和工业界，特别是制药和生物技术公司之间的合作，并已 保护参与组织的知识产权。人们普遍 项目和核心之间的保密性，根据推进化合物的需要共享数据，没有风险 到项目团队。由于MAVDA不保留任何知识产权，所有知识产权都属于主办机构或根据协议 与行业合作伙伴。MAC将执行以下具体目标：1）建立一个高效的 管理结构，为项目负责人和核心主管提供必要的监督和指导， 有效地整合了科学顾问委员会，作为发现过程中的战略顾问，并促进 科学交流; 2）最大限度地配置资源，优先复合发展， 通过支持以下方面的密切互动，实现“进行/不进行”决策和资源分配的关键指标 项目负责人和核心主管，并安排定期审查; 3）每年评估项目绩效， 准备中期和年终报告; 4）征集和管理开发和指导研究项目; 5)协调这些研究的出版物、结果介绍和新闻稿，并制定一个 解决冲突和其他业务问题的管理计划; 6）建立一个内部组织机构， 解决材料转让协议、知识产权备案、许可的物流的结构 机会和谈判。

The MAVDA Administrative Core (MAC) will be established as an integrated, priority-setting consortium involving the Program Directors (PDs), a Business Director (BD), an internal MAVDA Leadership Team (MLT), and a Scientific Advisory Board (SAB) with programmatic involvement from NIAID to enhance potential product outcome in the form of antivirals against SAR-CoV-2 and other viruses with pandemic potential. The management function is designed to provide administrative support that facilitates the success of individual projects, promotes effective integration and allocation of support functions and resources, and stimulates scientific exchange between MAVDA members, thus ensuring that the overall program achieves its objectives. The MAC will be overseen by co-PDs, Dr. David S. Perlin and Dr. Charles M. Rice, who will be supported by an experienced BD and appropriate support staff to coordinate and manage all administrative functions. To best advance MAVDA's objectives, the MAC will coordinate regular meetings of Project Leaders, Pharma/Biotech Partners, Core Directors, and SAB members. The meetings are designed to advance compounds through the discovery matrix enabling timely and objective ‘Go/No Go’ decision making. A secure web-based platform will be used to foster interactions between Projects and Cores. The MAC will facilitate an annual review meeting with the SAB, and a reverse site visit at NIAID. It will produce and submit the annual progress report to the NIH, and it will coordinate research publications, meeting presentations, reports and press releases. MAVDA is designed to encourage partnering among academia and industry, specifically Pharma and Biotech companies, and has protections in place to protect the intellectual property of participating organizations. There is universal confidentiality between projects and cores, with data shared as required to advance compounds and at no risk to the project team. As MAVDA retains no IP rights, all IP rights reside in the host institutions or per agreements with industry partners. The MAC will execute the following Specific Aims: 1) establish a highly efficient management structure that supplies essential oversight and guidance for Project Leaders and Core Directors, effectively integrates the Scientific Advisory Board as strategic advisors in the discovery process, and promotes scientific exchange; 2) maximize allocation of resources and prioritize compound development by establishing critical metrics for ‘Go/No Go’ decision making and resource allocations by supporting close interactions of Project Leaders and Core Directors and scheduling regular reviews; 3) annually assess project performance and prepare interim and year-end reports; 4) solicit and manage Developmental and Mentored Research Projects; 5) coordinate publications, presentations of results, and press releases from these studies and develop a managerial plan for conflict resolution and other operational issues; and 6) establish an internal organizational structure that addresses logistics for material transfer agreements, intellectual property filings, licensing opportunities, and negotiations.